CLChen Lv

Chen Lv

*This is an algorithmically generated author record based on publicly available information.

Chen Lv has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Lintuo Huang

    Department of Orthopedics The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

    4 shared publications
  • Lu Wang

    The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

    4 shared publications
  • Wenjun Lin

    The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

    4 shared publications
  • Zhengxiang Huang

    Department of Orthopedics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

    4 shared publications
  • Shengwu Yang

    The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang China

    3 shared publications
  • Xiongbai Zhu

    Department of Orthopedics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

    3 shared publications

Latest Publications

  • Open Access

    Novel targets and therapies of metformin in dementia: old drug, new insights

    by Wenxing Cui, Chen Lv, Panling Geng, Mingdi Fu, Wenjing Zhou, Mingxiang Xiong, Tian Li

    Dementia is a devastating disorder characterized by progressive and persistent cognitive decline, imposing a heavy public health burden on the individual and society. Despite numerous efforts by researchers in the field of dementia, pharmacological treatments are limited to relieving symptoms and fail to prevent disease progression. Therefore, studies exploring novel therapeutics or repurposing classical drugs indicated for other diseases are urgently needed. Metformin, a first-line antihyperglycemic drug used to treat type 2 diabetes, has been shown to be beneficial in neurodegenerative diseases including dementia. This review discusses and evaluates the neuroprotective role of metformin in dementia, from the perspective of basic and clinical studies. Mechanistically, metformin has been shown to improve insulin resistance, reduce neuronal apoptosis, and decrease oxidative stress and neuroinflammation in the brain. Collectively, the current data presented here support the future potential of metformin as a potential therapeutic strategy for dementia. This study also inspires a new field for future translational studies and clinical research to discover novel therapeutic targets for dementia.


  • BML‐111 inhibits osteoclast differentiation by suppressing the MAPK and NF‐κB pathways, alleviating deterioration of the knee joints in a CIA rat model

    by Lu Wang, Wei Su, Xiaohang Zheng, Wenjun Lin, Chen Lv, Shengwu Yang, Bicheng Chen, Chunwu Zhang

    Irreversible destruction of joints is the hallmark of rheumatoid arthritis (RA). Osteoclasts are the only bone‐resorbing cells and play an important role in joint rebuilding. BML‐111 (5(S),6(R),7‐trihydroxyheptanoic acid methyl ester, C8H16O5) is a synthetic lipoxin A4 agonist with antioxidant and anti‐inflammatory properties. The present study aimed to investigate the effect of BML‐111 on osteoclasts in vivo and in vitro, to investigate its therapeutic effect on joint destruction in RA. Cell Counting Kit‐8 assay and flow cytometry were used to exclude cytotoxic effects of BML‐111 to bone marrow‐derived macrophages (BMMs). Then, osteoclasts were differentiated in vitro from BMMs by used macrophage colony‐stimulating factor and receptor activator of nuclear factor‐κB ligand, and osteoclasts were observed following tartrate‐resistant acid phosphatase staining with or without BML‐111 treatment. Meanwhile, absorption pit assay and immunofluorescence staining of the fibrous actin ring were used to observe osteoclast function. Moreover, we examined mitogen‐activated protein kinase (MAPK) and nuclear factor‐κB (NF‐κB) activation. We established collagen‐induced arthritis in a rat model and, after treatment with BML‐111, joint swelling was measured and the knee joints were processed for histology. We also examined serum and tissue for osteoclastogenesis‐related markers. BML‐111 inhibited osteoclast formation and differentiation in a time‐ and concentration‐dependent manner, and downregulated the expression levels of MAPK and NF‐κB in vitro. Meanwhile, BML‐111 effectively alleviated joint structural damage and inhibited osteoclast formation in vivo. BML‐111 inhibited osteoclast formation and differentiation in vitro and in vivo, and delayed the progression of joint destruction.


  • Glucosamine suppresses oxidative stress and induces protective autophagy in osteoblasts by blocking the ROS/Akt/mTOR signaling pathway

    by Lintuo Huang, Wei Su, Ziqian Wu, Lidan Zheng, Chen Lv

    Oxidative stress is the crucial pathogenic factor in osteoporosis. Cell autophagy, a major form of self‐digestion, plays critical functions in different forms of stress by devouring harmful cytosolic proteins or organelles for the renewal of organelles and to maintain cellular homeostasis. Glucosamine (GlcN) has been widely utilized in treatments for patients with osteoarthritis‐related joint pain. It has potential antioxidant effects and its pharmacological effect in osteoblasts remains unclear. The present study aimed to investigate whether autophagy participates in the protective effects of GlcN in osteoblasts under oxidative stress and the possible mechanism. First of all, MC3T3‐E1 cells were treated with hydrogen peroxide (H2O2) to induce oxidative stress, as assessed by viability assays, apoptosis, the intracellular reactive oxygen species production. GlcN was capable of inducing autophagy and protected osteoblasts from those cytotoxic effects. Moreover, it significantly attenuated H2O2‐induced oxidative stress as measured by malondialdehyde, glutathione, nitrite, and superoxide dismutase levels. Importantly, the autophagy level increased in osteoblasts treated with GlcN as represented by an increase in both Beclin1 expression and the LC3 II/I ratio. Immunofluorescence analysis of autophagosomes also confirmed the above results. In addition, GlcN decreased the mammalian target of rapamycin (mTOR) and protein kinase B (Akt). However, the Akt activator (SC79) suppressed the autophagy level induced by GlcN in osteoblasts. Consequently, the antioxidant effects of GlcN were mediated, at least in part, by enhancing autophagy through the Akt/mTOR pathway. These results suggested that GlcN might be a promising candidate for osteoporosis treatment.


  • Knockdown of microRNA-203 reduces cisplatin chemo-sensitivity to osteosarcoma cell lines MG63 and U2OS in vitro by targeting RUNX2

    by Zhengxiang Huang, Lintuo Huang, Lue Liu, Lu Wang, Wenjun Lin, Xiongbai Zhu, Wei Su, Chen Lv

    Clinical studies have reported that miRNAs abnormal expression are associated with the generation of cisplatin-resistant to osteosarcoma. Our previous research found that miR-203 is downregulated in osteosarcoma cells and overexpressed miR-203 exerts antitumor properties on osteosarcoma cells. However, the role and mechanism of miR-203 in regulating the sensitivity of cisplatin in osteosarcoma cells remains unclear. This study aimed to investigate the effects of miR-203 in cisplatin therapy for osteosarcoma cells in vitro and determined the underlying mechanism. In this study, we found that miR-203 was significantly upregulated in osteosarcoma cells after exposure to cisplatin. miR-203 knockdown reduced the sensitivity of osteosarcoma cells to cisplatin by suppressing cell apoptosis, cell cycle arrest, and inducing invasion. Meanwhile, we found that miR-203 knockdown reduces the therapeutic sensitivity of osteosarcoma cells by upregulating RUNX2. Moreover, we found that RUNX2 silencing sensitizes osteosarcoma cells to chemotherapy treatment of cisplatin. In summary, our findings demonstrated that miR-203 knockdown reduces cisplatin chemo-sensitivity to osteosarcoma cells in vitro by targeting RUNX2, and speculated that miR-203 may be a target for drug resistance of osteosarcoma to cisplatin.


  • TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis

    by Chipeng Xiao, Chen Lv, Siyuan Sun, Heping Zhao, Hanzhi Ling, Man Li, Yang Qin, Jinhao Zhang, Jianguang Wang, Xinyu Yang

    In this study, we explored the effect of semaphorin5A (SEMA5A) on RA pathogenesis and its specific TSP1 domain on pannus formation. The expression of SEMA5A was detected in the synovium, the fibroblast-like synoviocytes (FLSs) and the SF of RA patients and healthy controls (HCs) by real-time quantitative PCR (q-PCR), immunohistochemistry staining, western blot and ELISA. SEMA5A-mAb intervention was performed to appraise the severity of joints in the CIA model. Transcriptome sequencing and bioinformatics analysis in SEMA5A-transfected FLSs from HCs were performed to screen differentially expressed genes after SEMA5A overexpression. An MTT assay in RA-FLSs, a chicken embryo allantoic membrane experiment and a tube formation experiment were used to clarify the influence of SEMA5A on cell proliferation and angiogenesis. Furthermore, a rescue experiment verified the function of the TSP1 domain of SEMA5A in the progress of RA with Sema5a−/− CIA mice. The expression of SEMA5A increased in RA compared with that in HCs. Simultaneously, SEMA5A-mAbs significantly attenuated joint injury and the inflammatory response in CIA models. In addition, transcriptome sequencing and angiogenesis-related experiments verified the ability of SEMA5A to promote FLS proliferation and angiogenesis. Moreover, TSP1 was proved to be an essential domain in SEMA5A-induced angiogenesis in vitro. Additionally, rescue of TSP1-deleted SEMA5A failed to reduce the severity of arthritis in a CIA model constructed with Sema5a −/− mice. In summary, upregulation of SEMA5A was first confirmed in pathological lesions of RA patients. Furthermore, treatment with SEMA5A-mAbs attenuated the progress of RA in the CIA model. Moreover, TSP1 was indicated as the key domain of SEMA5A in the promotion of pannus formation in RA. Graphical Abstract


  • Open Access

    Salidroside suppresses the growth and invasion of human osteosarcoma cell lines MG63 and U2OS in vitro by inhibiting the JAK2/STAT3 signaling pathway

    by Lintuo Huang, Zhengxiang Huang, Wenjun Lin, Lu Wang, Xiongbai Zhu, Xin Chen, Shengwu Yang, Chen Lv

    Previous research has reported that salidroside exerts antitumor properties on numerous types of tumor cells; however, its effect on osteosarcoma cells remains unknown. The present study aimed to investigate the effects of salidroside on the viability, apoptosis and invasion of osteosarcoma cells in vitro, and determine the underlying mechanism of action. The results of an MTT revealed that salidroside suppressed the viability of osteosarcoma cells (MG63 and U2OS cells) in a time‑ and concentration‑dependent manner. The results of cell morphological analysis (profile observations and Hoechst 33258 staining) and the detection of apoptosis by flow cytometry further indicated that the decrease in osteosarcoma cell viability induced by salidroside was associated with cell apoptosis. Western blot analysis not only confirmed these results but also suggested that salidroside induced the apoptosis of osteosarcoma cells by activating the caspase‑9‑dependent apoptotic pathway. In addition, we reported that salidroside induced G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells, as measured by flow cytometric cell cycle analysis and a Transwell invasion assay, respectively. Western blot analysis confirmed the aforementioned results. Furthermore, our findings demonstrated that salidroside induced the apoptosis, G0/G1 phase arrest and suppressed the invasion of osteosarcoma cells by inhibiting the janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway, as determined by western blot analysis. In summary, the findings of the present study suggested that salidroside may inhibit the progression of osteosarcoma by suppressing the growth and invasion of osteosarcoma cells. Furthermore, the investigations into the underlying mechanism demonstrated that salidroside exerted notable antitumor activity in osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.


  • MicroRNA-203 inhibits proliferation and invasion, and promotes apoptosis of osteosarcoma cells by targeting Runt-related transcription factor 2

    by Wenjun Lin, Xiongbai Zhu, Shengwu Yang, Xin Chen, Lu Wang, Zhengxiang Huang, Yewei Ding, Lintuo Huang, Chen Lv